Neumora Therapeutics to Participate in Upcoming Conferences in September
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company, which focuses on developing therapeutics for prevalent diseases through seven distinct programs, will attend the Wells Fargo Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 8), and H.C. Wainwright Global Investment Conference (Sept. 9).
Management will be available for one-on-one meetings at the Wells Fargo and Morgan Stanley events, while participating in a fireside chat at the H.C. Wainwright conference. The fireside chat will be webcast live and archived for 30 days on the company's website.
Neumora Therapeutics (Nasdaq: NMRA), azienda biofarmaceutica in fase clinica, ha comunicato la partecipazione a tre importanti conferenze per investitori nel settembre 2025. La società, che sviluppa terapie per malattie diffuse attraverso sette programmi distinti, sarà presente al Wells Fargo Healthcare Conference (4 set), al Morgan Stanley Global Healthcare Conference (8 set) e all'H.C. Wainwright Global Investment Conference (9 set).
Il management sarà disponibile per incontri one‑to‑one durante gli eventi di Wells Fargo e Morgan Stanley e parteciperà a un fireside chat all'H.C. Wainwright. Il fireside chat sarà trasmesso in diretta streaming e resterà archiviato per 30 giorni sul sito web della società.
Neumora Therapeutics (Nasdaq: NMRA), una compañía biofarmacéutica en fase clínica, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025. La empresa, que desarrolla terapias para enfermedades prevalentes mediante siete programas distintos, asistirá al Wells Fargo Healthcare Conference (4 de sept.), al Morgan Stanley Global Healthcare Conference (8 de sept.) y al H.C. Wainwright Global Investment Conference (9 de sept.).
La dirección estará disponible para reuniones one‑to‑one en los eventos de Wells Fargo y Morgan Stanley, y participará en un fireside chat en H.C. Wainwright. El fireside chat se emitirá por web en directo y quedará archivado durante 30 días en la web de la compañía.
Neumora Therapeutics(Nasdaq: NMRA)는 임상 단계의 바이오제약 회사로 2025년 9월에 개최되는 주요 투자자 콘퍼런스 3곳에 참가한다고 발표했습니다. 이 회사는 7개의 개별 프로그램을 통해 흔한 질환을 치료하는 치료제를 개발하고 있으며, Wells Fargo Healthcare Conference(9월 4일), Morgan Stanley Global Healthcare Conference(9월 8일), H.C. Wainwright Global Investment Conference(9월 9일)에 참석할 예정입니다.
경영진은 Wells Fargo와 Morgan Stanley 행사에서 일대일 미팅을 진행하며, H.C. Wainwright 콘퍼런스에서는 파이어사이드 채트에 참여합니다. 해당 파이어사이드 채트는 웹캐스트로 생중계되며 회사 웹사이트에 30일간 아카이브됩니다.
Neumora Therapeutics (Nasdaq: NMRA), société biopharmaceutique en phase clinique, a annoncé sa participation à trois grandes conférences pour investisseurs en septembre 2025. L'entreprise, qui développe des traitements pour des maladies répandues via sept programmes distincts, assistera au Wells Fargo Healthcare Conference (4 sept.), au Morgan Stanley Global Healthcare Conference (8 sept.) et au H.C. Wainwright Global Investment Conference (9 sept.).
La direction sera disponible pour des réunions en tête‑à‑tête lors des événements Wells Fargo et Morgan Stanley et participera à un fireside chat lors de la conférence H.C. Wainwright. Le fireside chat sera diffusé en direct via webcast et archivés pendant 30 jours sur le site web de la société.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen, das Therapien für weit verbreitete Krankheiten über sieben verschiedene Programme entwickelt, wird am Wells Fargo Healthcare Conference (4. Sept.), am Morgan Stanley Global Healthcare Conference (8. Sept.) und am H.C. Wainwright Global Investment Conference (9. Sept.) teilnehmen.
Das Management steht für Einzelgespräche bei den Veranstaltungen von Wells Fargo und Morgan Stanley zur Verfügung und wird an einem Fireside‑Chat bei H.C. Wainwright teilnehmen. Der Fireside‑Chat wird live per Webcast übertragen und 30 Tage lang auf der Firmenwebseite archiviert.
- None.
- None.
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.
- 2025 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday, September 4, 2025, in Boston, MA.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Members of management will be available for one-on-one meetings on Monday, September 8, 2025, in New York, NY.
- H.C. Wainwright 27th Annual Global Investment Conference: Members of management will participate in a fireside chat on Tuesday, September 9, 2025, at 1:00 p.m. ET in New York, NY.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
When is Neumora Therapeutics (NMRA) presenting at the H.C. Wainwright Conference?
How can investors access Neumora's H.C. Wainwright Conference presentation?
What conferences is Neumora Therapeutics (NMRA) attending in September 2025?
How many therapeutic programs does Neumora Therapeutics have in development?
